A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration, an administrative agency under the U.S. Department of Health and Human Services, by finding that drug manufacturers must obtain pre-approval from HRSA before implementing rebate models under the 340B Program.
